Chewing Gum for Smoking Cessation
Launched by THE UNIVERSITY OF HONG KONG · Jan 24, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into whether chewing gum can help people cut down on smoking or quit altogether. The researchers want to find out if people who chew gum report smoking fewer cigarettes and have better overall oral health compared to those who are trying to quit without any help. Participants in the study will receive some brief advice about quitting smoking and a booklet, and then they will either chew gum or try to quit on their own for one week.
To join this study, you need to be at least 18 years old, live in Hong Kong, and have been smoking at least one cigarette a day for the past three months. You should also be someone who either enjoys chewing gum or is willing to try it, and you need to be able to communicate in Cantonese. If you have communication challenges or are already part of another smoking cessation program, you won’t be eligible. Throughout the trial, you'll have the chance to share your experiences with the researchers through messaging apps like WhatsApp or WeChat.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Residents of Hong Kong aged 18 or above
- • 2. Smoking at least 1 cigarette per day over the past 3 months
- • 3. Have the habit of chewing gum or are willing to use chewing gum
- • 4. Participants who can communicate in Cantonese (including reading Chinese)
- • 5. Expressing an intention to quit or reduce smoking
- • 6. Capable of using instant messaging tools (e.g., WhatsApp, WeChat) for communication
- Exclusion Criteria:
- • 1. Having communication barriers (either physical or cognitive)
- • 2. Currently participating in other smoking cessation programs or services
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Pokfulam, Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported